×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVCR – novocure limited - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVCR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/13
08:31 am
nvcr
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at Piper Sandler from $28.00 to $42.00. They now have an "overweight" rating on the stock.
High
Report
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at Piper Sandler from $28.00 to $42.00. They now have an "overweight" rating on the stock.
12/2
06:11 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock, up previously from $24.00.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock, up previously from $24.00.
12/2
12:19 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock, up previously from $30.00.
Medium
Report
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock, up previously from $30.00.
12/2
07:08 am
nvcr
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $30.00 price target on the stock, up previously from $18.00.
High
Report
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $30.00 price target on the stock, up previously from $18.00.
12/2
07:00 am
nvcr
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
High
Report
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
11/27
07:00 am
nvcr
Novocure to Participate in Upcoming Investor Conferences
High
Report
Novocure to Participate in Upcoming Investor Conferences
11/21
01:46 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/21
07:07 am
nvcr
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma [Yahoo! Finance]
Medium
Report
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
Report
-2.8%
novocure limited - ordinary shares
7/25/2024
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
Report
-0.8%
novocure limited - ordinary shares
5/2/2024
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
Report
9.2%
novocure limited - ordinary shares
2/22/2024
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
Report
-3.2%
novocure limited - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/2
04:26 pm
nvcr
Form 144 NovoCure Ltd Filed by: GROENHUYSEN WILHELMUS CM
Neutral
Report
Form 144 NovoCure Ltd Filed by: GROENHUYSEN WILHELMUS CM
12/17
06:03 am
nvcr
Form 8-K/A NovoCure Ltd For: Aug 30
Low
Report
Form 8-K/A NovoCure Ltd For: Aug 30
12/2
07:00 am
nvcr
Form 8-K NovoCure Ltd For: Dec 02
High
Report
Form 8-K NovoCure Ltd For: Dec 02
11/6
04:27 pm
nvcr
Form 4 NovoCure Ltd For: Nov 02 Filed by: Paravasthu Mukund
Low
Report
Form 4 NovoCure Ltd For: Nov 02 Filed by: Paravasthu Mukund
11/4
04:35 pm
nvcr
Form 4 NovoCure Ltd For: Oct 31 Filed by: Puri Michal Nath
Low
Report
Form 4 NovoCure Ltd For: Oct 31 Filed by: Puri Michal Nath
11/4
04:34 pm
nvcr
Form 4 NovoCure Ltd For: Nov 01 Filed by: Leonard Frank X
Low
Report
Form 4 NovoCure Ltd For: Nov 01 Filed by: Leonard Frank X
11/4
04:33 pm
nvcr
Form 4 NovoCure Ltd For: Nov 01 Filed by: Paravasthu Mukund
Low
Report
Form 4 NovoCure Ltd For: Nov 01 Filed by: Paravasthu Mukund
10/30
07:02 am
nvcr
Form 8-K NovoCure Ltd For: Oct 29
Medium
Report
Form 8-K NovoCure Ltd For: Oct 29
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/16
Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
11.0%
7/25 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.070 ActVsEst 0.060 - Beat 8.6%
3/19 Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System 8.2%
3/4 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.8%
4/7 Novocure Ltd (NASDAQ: NVCR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a price target on the stock. 7.7%
5/23 FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma 7.3%
6/27 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 7.1%
8/14 Form 4 NovoCure Ltd For: Aug 12 Filed by: LEUNG GABRIEL 5.2%
10/31 NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
1/7 Novocure Ltd (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $91.00 price target on the stock. 5.2%
7/25 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.070 ActVsEst 0.060 - Beat 8.6%
3/19 Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System 8.2%
3/4 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.8%
4/7 Novocure Ltd (NASDAQ: NVCR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a price target on the stock. 7.7%
5/23 FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma 7.3%
6/27 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 7.1%
8/14 Form 4 NovoCure Ltd For: Aug 12 Filed by: LEUNG GABRIEL 5.2%
10/31 NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
1/7 Novocure Ltd (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $91.00 price target on the stock. 5.2%
TOP News Decliners
4/30
Q1/2020 3/31/2020 EPS 0.040 ZacksConsensus 0.050 ActVsEst (0.010) - Miss
-12.1%
3/20 German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany -10.5%
4/7 Novocure Ltd (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Co from $90.00 to $82.00. They now have an "overweight" rating on the stock. -9.6%
5/1 Novocure Ltd (NASDAQ: NVCR) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $78.00 price target on the stock. -8.4%
9/9 Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting -8.3%
3/10 Form 4 NovoCure Ltd For: Mar 06 Filed by: GROENHUYSEN WILHELMUS CM -8.1%
1/2 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Evercore ISI to an "outperform" rating. -7.9%
3/2 Form 4 NovoCure Ltd For: Feb 27 Filed by: Shah Pritesh -7.4%
10/25 Novocure Ltd (NASDAQ: NVCR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $79.00 price target on the stock. -6.6%
1/13 Form 8-K NovoCure Ltd For: Jan 10 -5.6%
3/20 German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany -10.5%
4/7 Novocure Ltd (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Co from $90.00 to $82.00. They now have an "overweight" rating on the stock. -9.6%
5/1 Novocure Ltd (NASDAQ: NVCR) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $78.00 price target on the stock. -8.4%
9/9 Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting -8.3%
3/10 Form 4 NovoCure Ltd For: Mar 06 Filed by: GROENHUYSEN WILHELMUS CM -8.1%
1/2 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Evercore ISI to an "outperform" rating. -7.9%
3/2 Form 4 NovoCure Ltd For: Feb 27 Filed by: Shah Pritesh -7.4%
10/25 Novocure Ltd (NASDAQ: NVCR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $79.00 price target on the stock. -6.6%
1/13 Form 8-K NovoCure Ltd For: Jan 10 -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: